Cargando…

High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs

EGFR-TKIs have been widely used in the first-line treatment of NSCLC patients harboring EGFR mutations. However, the prognosis indicators are limited. In the present study, the prognostic value of systemic immune-inflammation index (SII), neutrophil to lymphocyte ratio (NLR), and platelet to lymphoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Chao, Zhang, Na, Wang, Yapeng, Jiang, Shun, Lu, Min, Huang, Yan, Ma, Jin’an, Hu, Chunhong, Hou, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831201/ https://www.ncbi.nlm.nih.gov/pubmed/31415428 http://dx.doi.org/10.1097/MD.0000000000016875

Ejemplares similares

High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments
por: Zhao, Xiayan, et al.
Publicado: (2020)

Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs
por: Jiang, Shun, et al.
Publicado: (2021)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma
por: Ju, Qing, et al.
Publicado: (2021)

Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report
por: Jiang, Yiqian, et al.
Publicado: (2021)

Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review
por: Chen, Xiaoli, et al.
Publicado: (2023)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression
por: An, Na, et al.
Publicado: (2016)

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Mao, Chen, et al.
Publicado: (2015)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

High expression of PDGFA predicts poor prognosis of esophageal squamous cell carcinoma
por: Han, Na, et al.
Publicado: (2021)

NCAPD2 is a novel marker for the poor prognosis of lung adenocarcinoma and is associated with immune infiltration and tumor mutational burden
por: Li, Zihao, et al.
Publicado: (2023)

Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis
por: He, Canfeng, et al.
Publicado: (2021)

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs
por: Chiu, Tzu-Hsuan, et al.
Publicado: (2021)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

Lung adenocarcinoma with EGFR gene mutation metastatic to the uterine cervix: A case report
por: Wang, Yong, et al.
Publicado: (2020)

Breast metastasis from EGFR/ALK negative lung adenocarcinoma: A case report
por: Cao, Liyu, et al.
Publicado: (2020)

High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in lung adenocarcinoma: A STROBE compliant article
por: Feng, Hong, et al.
Publicado: (2018)

A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy
por: Hsieh, Meng-Che, et al.
Publicado: (2016)

Prognosis-related autophagy genes in female lung adenocarcinoma
por: Liu, Zhongxiang, et al.
Publicado: (2022)

Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma
por: Isaka, Tetsuya, et al.
Publicado: (2015)

GPR116 overexpression correlates with poor prognosis in gastric cancer
por: Zheng, Tian, et al.
Publicado: (2021)

High WFDC3 gene expression is associated with poor prognosis and reduced immune cells infiltration in pancreatic adenocarcinoma: A study using the TCGA database and bioinformatics analysis
por: Wu, Wei, et al.
Publicado: (2023)

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series
por: Li, Shih-Hong, et al.
Publicado: (2015)

ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma
por: Li, Shuang-Shuang, et al.
Publicado: (2020)

Lymphopenia Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma
por: Feng, Ji-Feng, et al.
Publicado: (2014)

Invasion Types Are Associated With Poor Prognosis in Lung Squamous Carcinoma Patients
por: Zhao, Yang, et al.
Publicado: (2015)

Overexpression of NEK3 is associated with poor prognosis in patients with gastric cancer
por: Cao, Yongfeng, et al.
Publicado: (2018)

Long-term survival in a patient with advanced non-smoking lung adenocarcinoma and no EGFR mutation after comprehensive therapy with EGFR-TKI-based therapy: A case report
por: Zhang, Qianyu, et al.
Publicado: (2022)

Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis
por: Lan, Bo, et al.
Publicado: (2022)

Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
por: Zhang, Ping, et al.
Publicado: (2018)

Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
por: Chen, Hui Jun, et al.
Publicado: (2021)

Association between systemic immune-inflammation index (SII) and survival outcome in patients with primary glioblastoma
por: Yang, Chao, et al.
Publicado: (2023)

Screening of significant biomarkers with poor prognosis in hepatocellular carcinoma via bioinformatics analysis
por: Sun, Quanquan, et al.
Publicado: (2020)

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report
por: Xu, Tongpeng, et al.
Publicado: (2017)

Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report
por: Zhao, Nan, et al.
Publicado: (2022)

Analysis of genes associated with prognosis of lung adenocarcinoma based on GEO and TCGA databases
por: Yu, Ye, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_flm2ac6m8b1qmlr35e0jsudvd1